Clinical Trial Goal
To find out:
- The highest dose of mRNA-2808 that's safe to give
- If mRNA-2808 is safe and works well to treat multiple myeloma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have multiple myeloma that has relapsed or is refractory
- Do not have plasma cell leukemia (PCL)
- Have been treated with all of the following. Your doctor can tell you this:
- An immunomodulatory drug (IMiD)
- A monoclonal antibody that targets CD38
- A proteasome inhibitor
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had an autologous (your own cells) BMT in the last 3 months
- Have not had CAR T-cell therapy or a similar therapy in the last 4 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
mRNA-2808 is a type of T-cell engager therapy that targets BCMA, FcRH5 and GPRC5D in certain cells.
You’ll get:
You’ll get:
- mRNA-2808 – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years.
The Food and Drug Administration (FDA) has not yet approved mRNA-2808.
Locations
Sponsors
lead: ModernaTX, Inc.
